Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis
…, A Ueyama, S Matsushima, M Torii, A Arimura - European journal of …, 2008 - Elsevier
Pirfenidone, a broad-spectrum antifibrotic agent, is known to have efficacy in certain fibrotic
disease models, and is under clinical trials in patients with idiopathic pulmonary fibrosis. We …
disease models, and is under clinical trials in patients with idiopathic pulmonary fibrosis. We …
A novel atopic dermatitis model induced by topical application with dermatophagoides farinae extract in NC/Nga mice
…, M Iduhara, S Takaki, M Deguchi, A Arimura - Allergology …, 2007 - Elsevier
Background Atopic dermatitis is a chronically relapsing inflammatory skin disease. Animal
models induced by relevant allergens play a very important role in the elucidation of the …
models induced by relevant allergens play a very important role in the elucidation of the …
[HTML][HTML] Association of a mutation in TRPV3 with defective hair growth in rodents
…, M Suzuki, I Oshima, K Tsukahara, A Arimura… - Journal of Investigative …, 2006 - Elsevier
DS-Nh mice and WBN/Kob-Ht rats are spontaneous hairless mutant rodent strains. These
animals develop spontaneous dermatitis under normal conditions. The non-hair Nh and Ht …
animals develop spontaneous dermatitis under normal conditions. The non-hair Nh and Ht …
Novel antiarthritic agents with 1, 2-isothiazolidine-1, 1-dioxide (γ-sultam) skeleton: cytokine suppressive dual inhibitors of cyclooxygenase-2 and 5-lipoxygenase
…, M Kobayashi, Y Hori, A Arimura… - Journal of medicinal …, 2000 - ACS Publications
Various 1,2-isothiazolidine-1,1-dioxide (γ-sultam) derivatives containing an antioxidant
moiety, 2,6-di-tert-butylphenol substituent, were prepared. Some compounds, which have a …
moiety, 2,6-di-tert-butylphenol substituent, were prepared. Some compounds, which have a …
[HTML][HTML] Impact of the Gly573Ser substitution in TRPV3 on the development of allergic and pruritic dermatitis in mice
…, T Hirasawa, T Sakata, T Horikawa, A Arimura - Journal of Investigative …, 2009 - Elsevier
We reported that the Gly573Ser substitution in transient receptor potential vanilloid 3 (TRPV3)
led to increased ion channel activity in keratinocytes and caused spontaneous …
led to increased ion channel activity in keratinocytes and caused spontaneous …
Prevention of allergic inflammation by a novel prostaglandin receptor antagonist, S-5751
A Arimura, K Yasui, J Kishino, F Asanuma… - … of Pharmacology and …, 2001 - ASPET
Prostaglandin (PG) D 2 , the major cyclooxygenase metabolite generated from immunologically
stimulated mast cells, is thought to contribute to the pathogenesis of allergic diseases …
stimulated mast cells, is thought to contribute to the pathogenesis of allergic diseases …
Cutting edge: STAT6 serves as a positive and negative regulator of gene expression in IL-4-stimulated B lymphocytes
AJ Schroder, P Pavlidis, A Arimura… - The Journal of …, 2002 - journals.aai.org
STAT6 plays an important role in IL-4-mediated B cell activation and differentiation. To
identify primary and secondary target genes of STAT6, gene expression profiles of IL-4-stimulated …
identify primary and secondary target genes of STAT6, gene expression profiles of IL-4-stimulated …
Influence of TRPV3 mutation on hair growth cycle in mice
…, T Hirasawa, K Higashino, Y Gahara, A Arimura… - Biochemical and …, 2007 - Elsevier
We recently reported that Gly573Ser substitution of the transient receptor potential cation
channel, subfamily V member 3 (TRPV3) caused hair loss in DS-Nh mice. To further elucidate …
channel, subfamily V member 3 (TRPV3) caused hair loss in DS-Nh mice. To further elucidate …
Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent
…, M Soga, M Deguchi, K Yasui, A Arimura - Bioorganic & medicinal …, 2012 - Elsevier
The discovery of novel CB2 ligands based on the 3-carbamoyl-2-pyridone derivatives by
adjusting the size of side chain at 1-, 5- and 6-position is reported. The structure–activity …
adjusting the size of side chain at 1-, 5- and 6-position is reported. The structure–activity …
[HTML][HTML] A phase I/II study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer
…, N Cresti, J Posner, Y Takeda, A Arimura… - Breast Cancer …, 2020 - Springer
Background Epertinib (S-222611) is a potent reversible inhibitor of HER2, EGFR and HER4.
This trial evaluated the safety, tolerability, pharmacokinetics and antitumour activity of daily …
This trial evaluated the safety, tolerability, pharmacokinetics and antitumour activity of daily …